Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012;2013:1–11.

Google Scholar 

Kronbichler A, Lee KH, Denicolo S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci. 2020;21(19):7319.

CAS  Article  Google Scholar 

Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Prim. 2020;6(1):71.

Article  Google Scholar 

Thompson A. Tarascon pocket rheumatologica. Fourth. Sudbury, Massachusetts: Jones and Bartlett Publishers, 2010.

Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020;75(1):124–37.

CAS  Article  Google Scholar 

Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev. 2010;9(12);812–9.

Sacoto G, Boukhlal S, Specks U, Flores-Suárez LF, Cornec D. Lung involvement in ANCA-associated vasculitis. Presse Med. 2020;49( 3);104039.

Watts RA, Al-Taiar A, Scott DGI, Macgregor AJ. Prevalence and incidence of Wegener’s granulomatosis in the UK general practice research database. Arthritis Rheum. 2009;61(10):1412–6

Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatol (Oxford). 2009;48(12):1560–5.

Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota. Arthritis Rheum. 2017;69(12):2338–50.

• Fisher JH, Kolb M, Algamdi M, Morisset J, Johannson KA, Shapera S, et al. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulm Med. 2019;19(1):223. A large cohort study, that helped determine the frequency of ANCA positivity in ILD in Canada.

Ahn JK, Hwang J-W, Lee J, Jeon CH, Cha H-S, Koh E-M. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2012;32(10):2979–86.

Article  Google Scholar 

• Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev. 2021;30(162):210123. A great review on AAV-ILD.

Article  Google Scholar 

Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990;65(6):847–56.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–87.

•• Sun X, Peng M, Zhang T, Li Z, Song L, Li M, et al. Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. BMC Pulm Med. 2021;21(1):88. A great series and review on AAV-ILD.

Johannson KA, Kolb M, Fell CD, Assayag D, Fisher J, Churg A, et al. Evaluation of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(3):133–41.

Google Scholar 

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.

Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608–15.

Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):1–9.

Google Scholar 

Hozumi H, Enomoto N, Oyama Y, Kono M, Fujisawa T, Inui N, et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias. Lung. 2016;194(2):235–42.

CAS  Article  Google Scholar 

Hozumi H, Oyama Y, Yasui H, Suzuki Y, Kono M, Karayama M et al. Clinical significance of myeloperoxidase-antineutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS One. 2018;13(6):e019965.

•• Liu GY, Ventura IB, Achtar-Zadeh N, Elicker BM, Jones KD, Wolters PJ, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis. Chest. 2019;156(4):715–23. A large cohort study, that helped determine the frequency of ANCA positivity in ILD in North America.

Article  Google Scholar 

• Fidler LM, Kandel S, Fisher JH, Mittoo S, Shapera S. Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(2):e2021015. A study on the utility of ANCA testing in ILD.

•• Maillet T, Goletto T, Beltramo G, Dupuy H, Jouneau S, Borie R et al. Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor. J Autoimmun. 2020;106:102338. A series of AAV-ILD and its prognostic implications.

Wurmann P, Sabugo F, Elgueta F, Mac-Namara M, Vergara K, Vargas D, et al. Interstitial lung disease and microscopic polyangiitis in chilean patients. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):37–42.

PubMed  PubMed Central  Google Scholar 

•• Watanabe T, Minezawa T, Hasegawa M, Goto Y, Okamura T, Sakakibara Y et al. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study. BMC Pulm Med. 2019;19(1):194. Another series of AAV-ILD and its prognostic implications.

•• Baqir M, Yi EE, Colby TV, Cox CW, Ryu JH, Specks U. Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2019;36(3):195–201. Another series of AAV-ILD and its radiological features.

Google Scholar 

•• Kwon M, Lee AS, Mira-Avendano I, Rojas CA, Grage R, Abril A. Interstitial lung disease in antineutrophil cytoplasmic antibody–associated vasculitis patients. JCR: J Clin Rheumatol [Internet]. 2021 Dec;27(8):324–30. Available from: https://journals.lww.com/https://doi.org/10.1097/RHU.0000000000001357. Another series of AAV-ILD.

Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: Is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum. 2007;56(6).

Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102(10):1392–8.

Article  Google Scholar 

Tanaka T, Otani K, Egashira R, Kashima Y, Taniguchi H, Kondoh Y, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med. 2012;106(12):1765–70.

Foucher P, Heeringa P, Petersen AH, Huitema MG, Brouwer E, Cohen Tervaert JW et al. Antimyeloperoxidase-associated lung disease. Am J Respir Crit Care Med. 1999;160(3).

Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J. 2011;37(6).

Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.

Yoshida M, Yamada M, Sudo Y, Kojima T, Tomiyasu T, Yoshikawa N et al. Myeloperoxidase anti‐neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti‐neutrophil cytoplasmic antibody‐associated microscopic polyangiitis. Nephrology (Carlton). 2016;21(7):624–9.

Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood. 2012;120(15):3007–18.

• Namba N, Kawasaki A, Sada K, Hirano F, Kobayashi S, Yamada H, et al. Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2019;78(8):1144–6. A genetic study in AAV-ILD, suggesting some occasional genetic predisposing alleles.

Article  Google Scholar 

• Kawasaki A, Namba N, Sada K, Hirano F, Kobayashi S, Nagasaka K, et al. Association of TERT and DSP variants with microscopic polyangiitis and myeloperoxidase-ANCA positive vasculitis in a Japanese population: a genetic association study. Arthritis Res Ther. 2020;22(1):246. Another genetic study in AAV-ILD, suggesting some occasional genetic predisposing alleles.

CAS  Article  Google Scholar 

Schnabel A, Holl-Ulrich K, Dalhoff K, Reuter M, Gross WL. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10(12):2738–43.

CAS  Article  Google Scholar 

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363.

Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609.

CAS  Article  Google Scholar 

Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31.

CAS  Article  Google Scholar 

Pagnoux C, Mahr A, Hamidou MA, Boffa J-J, Ruivard M, Ducroix J-P et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26).

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–80.

Article  Google Scholar 

Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009;68(3):404–7.

CAS  Article  Google Scholar 

Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Medicine. 2014;93(24):340–9.

CAS  Article  Google Scholar 

•• Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27. A major trial in ILD on nintedanib, an antifibrotic agent.

CAS  Article  Google Scholar 

• Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–86. Another trial in ILD on pirfenidone, an antifibrotic agent.

• Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–57. Another trial in ILD on pirfenidone, an antifibrotic agent.

• Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–28. Another major trial in ILD on nintedanib, an antifibrotic agent.

CAS  Article  Google Scholar 

Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol.  2022;18(2):85–96.

• Fisher JH, Johannson KA, Assayag D, Morisset J, de Boer K, Manganas H, et al. Long-term monitoring of patients with fibrotic interstitial lung disease: a Canadian Thoracic Society Position Statement. Can J Respir Crit Care Sleep Med. 2020;4(3):147–55. A review and guidance on how to monitor ILD patients.

Google Scholar 

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

Article  Google Scholar